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Meibomian gland dysfunction (MGD) is a common and chronic disorder that has a signiﬁcant adverse
impact on patients' quality of life. It is a leading cause of evaporative dry eye disease (DED), as meibomian
glands play an important role in providing lipids to the tear ﬁlm, which helps to retard the evaporation of
tears from the ocular surface. MGD is also often present in conjunction with primary aqueous-deﬁcient
DED. Obstructive MGD, the most commonly observed type of MGD, is the main focus of this article. MGD
is probably caused by a combination of separate conditions: primary obstructive hyperkeratinization of
the meibomian gland, abnormal meibomian gland secretion, eyelid inﬂammation, corneal inﬂammation
and damage, microbiological changes, and DED. Furthermore, skin diseases such as rosacea may play a
part in its pathology. Accurate diagnosis is challenging, as it is difﬁcult to differentiate between ocular
surface diseases, but is crucial when choosing treatment options. Ocular imaging has advanced in recent
years, providing ophthalmologists with a better understanding of ocular diseases. This review presents a
literature update on the 2011 MGD workshop and an optimized approach to accurate diagnosis of MGD
using currently available methods and tests. It also outlines the emerging technologies of interferometry,
non-contact meibography, keratography and in vivo confocal laser microscopy, which offer exciting
possibilities for the future. Selected treatment options for MGD are also discussed.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).mology, University Hospital
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Meibomian gland dysfunction (MGD) is a leading cause of
evaporative dry eye disease (DED) and is one of the most common
diseases encountered in the ophthalmology clinic [1e3]. The
impact of MGD on patients can be severe, with a negative effect on
their quality of life that may lead to a loss of productivity [4,5].
Obstructive MGD is the most commonly observed type of MGD [6]
and is the main focus of this article. Obstructive MGD is associated
with changes such as hypertrophy of the duct epithelium and
keratinization of the oriﬁce epithelium [6]. Terminal ductnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the ocular surface [6].
The 2011 International Workshop on MGD represented a sig-
niﬁcant advance in the understanding, classiﬁcation, diagnosis and
treatment of the disease [7]. The classiﬁcation system developed by
the International Workshop recognizes that although MGD may
occur without DED, MGD may lead to evaporative DED when signs
are sufﬁciently severe [7]. Nevertheless, some confusion persists
around whether MGD is primary or secondary to DED, whether
MGD is part of the vicious circle of events of DED, and which
symptoms are related to MGD and which are related to DED [7e9].
The causative association between MGD and DED is strongly
debated; MGD may lead to DED through a process of events that
involves inﬂammation, but equally, the surface inﬂammation of the
eyelid margin in DEDmay affect meibomian gland morphology and
function, giving rise to MGD [8]. Some types of MGD are also
associated with ocular rosacea and other skin sebaceous gland
conditions [10].
General ophthalmologists face a challenge in differentiating
MGD from other forms of DED and in identifying subforms such as
dermatitis-associatedMGD, to inform their management decisions.
This review presents the results of discussions held by the OCEANFig. 1. Importance of MGD in the vicious circle of MGD-related DED pathology. DED, dry eye
permission from Baudouin et al. [13]. The ﬁrst circle illustrates the proposal that MGD, diagno
and mites in the glands, potentially resulting in stagnation of the meibum and leading to
changes in the tear ﬁlm owing to an increase in the melting temperature of the meibum a
concentration of free fatty acids, secondary to increasing the activity of bacterial lipases, wh
how MGD may lead to a decrease in the lipid layer of the tear ﬁlm, giving rise to hyperosm
activity, leading to keratinization of the meibomian gland ducts.group in 2014 and aims to provide a practical guide to under-
standing and diagnosing MGD for the general ophthalmologist.
New and emerging techniques for diagnosing all forms of MGD are
examined for their potential usefulness, and some guidance for
selecting the most appropriate treatment is provided. In addition,
the expanded version of the vicious circle of DED that encompasses
MGD pathology is presented (Fig. 1) [11e13].2. MGD: pathology and prevalence
Meibomian glands are found in the upper and lower eyelids, and
their role is to secrete lipids (meibum) onto the ocular surface that
forms the outermost layer of the tear ﬁlm; these lipids spread
easily, promoting stability and protecting against evaporation
[6,14]. MGD-related DED is currently deﬁned as ‘a chronic, diffuse
abnormality of the meibomian glands, commonly characterized by
terminal duct obstruction and/or qualitative/quantitative changes
in the glandular secretion. It may result in alteration of the tear ﬁlm,
symptoms of eye irritation, clinically apparent inﬂammation and
ocular surface disease.’ [7] It is beyond the scope of this paper to
describe in detail the pathology of MGD; however, the OCEAN
group recognizes that MGD is a heterogeneous condition anddisease; MG, meibomian gland; MGD, meibomian gland dysfunction. Reproduced with
sed by blockage/atrophy of meibomian glands, could lead to a proliferation of microbes
the release of enzymes (activating inﬂammation). In turn, this may lead to qualitative
s it becomes more viscous. The modiﬁed ﬂora is thought to induce an increase in the
ich may induce apoptosis of the ocular surface epithelial cells. The second circle shows
olarity of the tear ﬁlm and inﬂammation e a combination that could induce enzyme
G. Geerling et al. / The Ocular Surface 15 (2017) 179e192 181proposes an integrated aetiological hypothesis based on existing
evidence inwhichMGD arises from any combination of six separate
conditions: primary obstructive hyperkeratinization of the meibo-
mian gland, abnormal meibomian gland secretion, eyelid inﬂam-
mation, corneal and conjunctival inﬂammation and epithelial
damage, microbiological changes (e.g. Staphylococcus sp., Propio-
nibacterium acnes and Demodex sp.) and DED [1,7,9,15]. Hyper-
keratinization of the meibomian glands causes obstruction,
degenerative gland dilation, and atrophy. It is proposed that
hyperkeratinization can be exacerbated by changes in normal
meibomian lipids and the generation of free fatty acids, which may
result from the release of lipid-degrading enzymes (esterases and
lipases) by pre-existing commensal bacteria of the eyelids, causing
epithelial irritation that promotes inﬂammation and stimulates
further hyperkeratinization with cicatricial changes [12,16,17]. In
the aforementioned sequence of events, the growth of commensal
bacteria, and the consequent release of lipid-degrading enzymes, is
postulated to occur as a result of the stagnation of meibum
following meibomian gland obstruction [16]. Infection with
commensal bacteria such as Staphylococcus aureus is an established
pathogenic cause of chronic blepharitis, an inﬂammatory condition
of the eyelid margin previously referred to synonymously with
MGD but in recent years acknowledged as a related clinical con-
dition that can develop in later stages of MGD, or independently
[9,16]. Staphylococcus aureus is a commensal bacterium of skin and
mucosa in the nose vestibule, but it can develop into an important
opportunistic pathogen [18]. Increased bacterial growth associated
with MGD-related blepharitis may arise from a different mecha-
nism than that of meibum stagnation in MGD, but the downstream
effects are proposed to manifest as inﬂammation and further
hyperkeratinization [16]. Unlike chronic blepharitis, however, the
pathogenic role of bacterial infection in inﬂammation associated
with MGD remains to be clariﬁed [16].
Skin diseases such as rosacea or seborrhoeic dermatitis also play
a part in MGD pathophysiology, and recent evidence has shown
that microbial and pathogenic mechanisms (along with neuro-
vascular changes, chronic inﬂammation and dysregulation in im-
munity) may be involved in rosacea pathophysiology. Intestinal
microbiota have been shown to play a role in the function of
sebaceous glands, as signiﬁcantly higher incidence rates of small
intestine bacterial overgrowth (SIBO) have been identiﬁed in pa-
tients with rosacea compared with controls [19,20].
The high prevalence of MGD among normal patients presenting
for routine vision testing was documented many years ago [21].
However, precise estimates of MGD prevalence are elusive, as the
rates vary geographically, and until recently, a clear deﬁnition of
MGD was lacking. Approximately 60% of Asian populations are re-
ported to have MGD, but in Caucasians, the rate is less than 20% [7].
Prevalence is also affected by age, with reports of MGD in 33% of
patients aged < 30 years and in 72% of patients aged  60 years in
an Asian population [22].
Approximately 90% of patients with ocular rosacea (8e50% of all
rosacea cases [23]) show eyelid changes (for example, inﬂamma-
tion of the lid margin [24]) that are similar to those observed in
patients withMGD [10]. Despite the frequent associationwithMGD
[23], ocular rosacea is often underdiagnosed by ophthalmologists
[25]. The ability to differentiate between cases of MGD without
dermatitis and rosacea-associated MGD is important, as the latter
form has a worse prognosis [24].
3. The role of MGD in DED
One of the outcomes arising from the 2011 International
Workshop on MGD was a clariﬁcation of the association between
MGD and DED [7]. DED and MGD were reported in 11% and 35% ofpatients, respectively, in a population-based study that used an
array of subjective and objective tests, in addition to examination of
the eyelid margins andmeibomian gland, to identify ocular disease.
Almost half of the patients with DEDwere found to haveMGD, with
the presence of MGD strongly associated with the symptoms and
signs of DED, even when adjusted for age and gender [26]. The
strength of the association between symptoms of MGD and DED
has not been examined, although it is generally understood that
there is marked symptom overlap between the two conditions [7].
In the healthy eye, the meibomian glands provide the meibum
that forms the lipid layer of the tear ﬁlm and fromwhich the layer is
replenished [9]. Given this substantial codependence between the
tear ﬁlm and the meibomian glands, differentiating MGD-related
DED from other ocular surface diseases can be challenging [27].
On the other hand, tests such as the tear ﬁlm break-up time (TBUT)
have been effectively harnessed to diagnose evaporative DED and
MGD-related DED through measurement of tear ﬁlm instability, a
core mechanism of DED that reﬂects an alteration in the tear ﬁlm
layer and, by extension, meibomian gland function, among other
factors [9]. The International Workshop on MGD recommended a
sequence of tests, including TBUT, ocular surface staining, Schirmer
score and tear volume, to facilitate the differential diagnosis of
MGD-related evaporative DED and aqueous-deﬁcient DED [9]. In
addition to these tests, examination of other innate mechanisms
that underlie MGD and DED pathogenesis may be used to differ-
entiate MGD-related DED from other forms of DED. For example,
expression of acidic mammalian chitinase (AMCase) is increased in
patients with MGD compared with patients with Sj€ogren's syn-
drome, while the proinﬂammatory matrix metalloproteinase 9
(MMP9) is expressed at higher levels in patients with Sj€ogren's
syndrome than in those with MGD (although the expression in
patients with MGD is still higher than that in the general popula-
tion) [28,29]. While these preliminary data are encouraging, the
effect of disease severity on marker levels is just one of the factors
requiring further clariﬁcationwith regard to the diagnostic value of
AMCase and MMP9 in MGD-related DED. Conversely, MGD-related
blepharitis can induce a chronic response of the ocular surface that
makes it difﬁcult to differentiate MGD from other forms of DED
with a different pathogenesis, as the clinical features are compa-
rable [30].
The relationship between MGD and DED is clearly illustrated in
the vicious circle of DED, which indicates the central role of tear
ﬁlm instability [11]. An expanded version of the vicious circle elu-
cidates the pathology of MGD and its relationship to DED (Fig. 1)
[12,13]. The ﬁrst circle illustrates the proposal that MGD, diagnosed
by blockage/atrophy of meibomian glands, could lead to a prolif-
eration of microbes and mites in the glands, potentially resulting in
stagnation of the meibum and leading to the release of enzymes
(activating inﬂammation) [16,28,31]. In turn, this may lead to an
increase in the melting temperature as the meibum becomes more
viscous. The modiﬁed ﬂora is thought to induce an increase in the
concentration of free fatty acids, secondary to increasing the ac-
tivity of bacterial lipases, which may induce apoptosis of the ocular
surface epithelial cells [29,32]. While the causal role of bacteria in
MGD has not been conclusively established for all forms of MGD,
there is evidence to support the importance of bacterial products
(such as lipases) of S. aureus and P. acnes, for example, in the
pathogenesis of MGD [16]. The role of Demodex mites in the path-
ogenesis of DED and MGD has not been proven or fully elucidated,
although a recent confocal microscopy study highlighted an asso-
ciation between Demodex infestation (of the lower eyelid lash fol-
licles and meibomian glands) and MGD in patients with DED that
was not due to contamination [31]. The second circle shows how
MGDmay lead to a decrease in the lipid layer of the tear ﬁlm, giving
rise to hyperosmolarity of the tear ﬁlm and inﬂammation e a
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nization of the meibomian gland ducts. Microbial involvement
(P. acnes) is implicated in a recently characterized inﬂammatory
form of MGD, meibomitis-related keratoconjunctivitis (MRKC), that
is frequently seen in younger patients and shares signs and
symptoms with childhood ocular rosacea [33,34]. Systemic anti-
microbials targeting P. acnes have demonstrated efﬁcacy in MRKC,
highlighting the potential importance of eradicating pathogenic
bacteria in some forms of MGD [33,34].4. Diagnosing MGD
MGD is a main cause of evaporative DED (also known as lipid-
deﬁcient DED) [3,35e37], although other pathogenic factors of
evaporative DED include low blink rate; incomplete blinking; pre-
servatives in topical ophthalmic medications; contact lens wear;
ocular surface disease, including allergic eye disease; and disorders
of the eyelid anatomy and function [17]. MGD also often exists in
conjunctionwith aqueous-deﬁcient DED [7,38]. The contribution of
MGD to the severity of aqueous-deﬁcient DED is unclear and re-
quires further study [7]. It may be speculated from the proposed
expanded vicious circle of DED (Fig. 1) that the clinical course of
aqueous-deﬁcient DED worsens with increasing severity of MGD.
Diagnosing MGD can be problematic, as the symptoms are not
speciﬁc to the disease, and, currently, questionnaires for assessing
symptomatology are mainly directed towards aqueous-deﬁcient
DED. There is a need for a standardized clinical assessment and
diagnosis of MGD that also includes the identiﬁcation of MGD-
associated sebaceous skin diseases. With this consideration, it is
best to examine the clinical signs ﬁrst. Much useful information is
available from the 2011 report on the diagnosis of MGD [9], but
newer diagnostic technologies are now emerging, and the topic of
diagnosis needs revisiting. In clinical studies, the consistency of the
diagnostic process remains poor, as was shown in a review that
evaluated the interexaminer reliability of grading clinical variables
associated with MGD [39]. The authors concluded that consistency
ranged from fair to moderate across different measured clinical
outcomes, namely acini appearance, gland dropout, eyelid debris
and telangiectasias [39].
MGD can be asymptomatic or symptomatic, although with
progression, asymptomatic MGD (detected by gland expression or
meibography) may develop into symptomatic MGD [9]. In addition,
MGD may develop alone or in association with ocular surface dis-
ease (OSDs) or it may occur secondary to other ocular disorders,
including rosacea [9]. Early treatment during the asymptomatic
stage of MGD may delay progression to the symptomatic stage and
reverse the pathological events of MGD [9]. Symptomatic MGDmay
be detected via its key clinical signs [9], which include meibomianTable 1
Methods for assessing meibomian gland function [9,126].
Technology Function
Meibomian gland expression Application of pressure (digital or with an in
Meibometry Quantiﬁcation of the amount of lipids at the
Keratography Permits visual assessment of the topography
Newer techniques
Meiboscopy/meibography Allows observation of the morphology of me
observation or photodocumentation
Visualization of the meibomian glands can be
contact)
Interferometry Provides visual analysis of the lipid layer of t
In vivo confocal laser microscopy High-resolution scans enable measurement o
of morphological changes of the glands
Evaporimetry Detects real-time changes in tear evaporatio
TBUT, tear ﬁlm break-up time.gland dropout, as measured by the loss of acinar tissue (detected by
meibography, whereby the meibomian glands are viewed in
silhouette by transillumination through the everted eyelids, using a
clearly deﬁned technique to score the meibomian gland dropout),
altered meibomian gland secretion (assessed by applying digital
pressure to the tarsal plate) and changes in eyelid morphology
(evaluated by slit-lamp microscopy). Several techniques are in
current use for assessing meibomian gland morphology and func-
tion (Table 1).
Many of the clinical signs and symptoms of rosacea-associated
MGD are similar to those of MGD alone [24]. However, in the
absence of speciﬁc diagnostic criteria for rosacea-associated MGD,
diagnosis is based on the consideration of MGD as a clinical
component of ocular rosacea, whereby conﬁrmation requires the
presence of symptom criteria for the separate clinical conditions
[24]. Rosacea-associated MGD may be identiﬁed by the presence of
a number of features: foreign body sensation, dryness or itching,
photosensitivity, telangiectasia of the lid margin, periorbital
oedema, clinical signs of lid inﬂammation, chalazia and the pres-
ence of chronic staphylococcal infection as manifested by hordeola
(styes) [25,40]. Whether rosacea-associated MGD is, by virtue of its
terminology, a combination of the two clinical conditions or
whether it represents a different form of MGD remains to be
determined. Nevertheless, rosacea-associated MGD is commonly
associated with a poorer prognosis than MGD alone [24].
Following an initial observation of the patient's face for signs of
dermatological disease, a recommended diagnostic sequence for
assessment of DED and MGD that follows the principle of per-
forming the most invasive tests last should be used (Fig. 2).
i. Patient questionnaire. While there are no speciﬁc question-
naires designed for the assessment of MGD, there are several
that are currently used for assessing DED symptomatology:
McMonnies, Schein, Canadian Dry Eye Epidemiology Study
(CANDEES), Ocular Surface Disease Index (OSDI), Interna-
tional Sj€ogren's Classiﬁcation, Women's Health Study, Dry
Eye Questionnaire (DEQ), Ocular Surface Disease e Quality of
Life (OSD-QoL) and Impact of Dry Eye on Everyday Life
(IDEEL) [17]. A newer questionnaire, Standard Patient Eval-
uation of Eye Dryness (SPEED), has fewer questions and
easier interpretability than the OSDI and seems to correlate
better with the parameters of evaporative DED, while OSDI
values have a better correlation with aqueous-deﬁcient DED
[41]. See Table 2 for further information on these question-
naires. In addition, clinical scorecards can be used to grade
the features and severity of rosacea [40].
ii. Tear break-up time. TBUT is a surrogate indicator of tear ﬁlm
stability. Low scores (<10 s) can indicate an inadequatestrument) to eyelids to quantify and qualify meibomian gland expression
eyelid margin by blotting lipids onto a tape applied to the eyelid
of the corneal surface and non-invasive TBUT
ibomian glands and quantiﬁcation of meibomian gland dropout by clinical
by transillumination (through the eyelid) or use of infrared light and camera (non-
he tear ﬁlm using broad-spectrum white light interferometry
f acinar density (number of glands/mm2), mean acinar diameter and visualization
n rates and examines tear ﬁlm stability
Fig. 2. A practical diagnostic sequence for meibomian gland dysfunction alone or in the presence of aqueous- or lipid-deﬁcient dry eye disease. *Refer to Table 1 for further in-
formation on technologies to assess meibomian gland dysfunction. Based on the International Dry Eye Workshop 2007 [17] and OCEAN panel expert opinion.
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tear ﬁlm and are often related to a compromised lipid layer
owing to meibomian gland dysfunction, although this can
also result from a deﬁcient aqueous layer [9]. TBUT score
does not provide a differential diagnosis between MGD and
DED [42].
iii. Ocular surface staining. Ocular surface damage is a common
consequence of tear ﬁlm instability associated with MGD,
although it is not necessarily diagnostic to MGD. It can be
quantiﬁed by grading the staining of the cornea (using
ﬂuorescein) and conjunctiva (using lissamine green) [9]. In
the clinical experience of the authors, staining along the
upper and lower lid margin more is likely to be associated
withMGD or some form of blepharitis, and central staining is
more likely to be related to aqueous-deﬁcient dry eye.
iv. Eyelid morphology/margin examination. Along with a low
TBUT, compromised eyelid morphology (where the eyelid
margin is irregular, not the eyelid itself) is classically sug-
gestive of MGD [43]. Examination should include an assess-
ment of the eyelid margin (looking for thickening,
telangiectasia/vascularity and notching) and oriﬁces (check-
ing the number and condition of the eight central glands of
each eyelid) [9,44]. In early MGD, subtle morphological
changes may not be apparent upon physical examination.
Blackie et al. have described nonobvious obstructive MGD
(NOMGD), which seems to be the precursor to obstructive
MGD [45]. In NOMGD the classical clinical signs of MGD (e.g.
irregular lid margin, lid margin thickening, and meibomian
gland oriﬁce pouting) are not apparent and the diagnosis is
made on the basis of meibomian gland expression (see point
v. below) [45].
v. Meibomian gland expression. The presence of MGD can be
conﬁrmed by assessment of meibomian gland expression(quantity, quality and expressibility of meibum) and gland
dropout [9,44]. Indeed, the only method to determine
whether a speciﬁc meibomian gland is functional and
capable of providing secretion is to observe the secretion
expressed from that gland [9]. Physical force is applied to the
eyelid either by digital pressure, or with the use of a hand-
held instrument to provide standardized force to the eyelid
[9]. The eyelid is simultaneously observed under suitable
magniﬁcation to assess the gland expressibility, lipid volume,
and lipid quality [9].
vi. Schirmer test. This should ideally be the ﬁnal test performed,
as it can affect the results of the ocular surface staining tests.
A Schirmer score 5 mm/5 min (without anaesthesia) in-
dicates dry eye severity levels of 2e3 and is strongly indic-
ative of aqueous-deﬁcient DED [17,46], while patients with
lipid-deﬁcient DED may have reﬂex excessive or moder-
ately reduced tear production [30]. By contrast, reduced tear
production has also been observed in rosacea-associated
MGD [47]. Therefore, the Schirmer test may be useful in
differentiating between primary MGD (usually normal
Schirmer test result) and conditions associated with reduced
tear production and stability, such as rosacea associated with
MGD [24], ocular rosacea [48e51] and aqueous-deﬁcient
DED, but it cannot be considered as a robust screening test
because there are situations where MGD and aqueous-
deﬁcient DED coexist.5. Emerging technologies for the diagnosis of MGD
While the diagnostic test sequence described above offers
ophthalmologists practical guidance on the best approach to
identify MGD and MGD-related diseases using current tests and
Table 2
Patient questionnaires.
Questionnaire Description Pros Cons
Canadian Dry Eye Epidemiology
Study (CANDEES) [127]
13 questions: environmental
triggers, symptom severity,
allergies
Simple and fast Tool designed for epidemiological
studies and not for clinical
assessment
Includes demographic data as well
as QoL symptoms
Dry Eye Questionnaire (DEQ) [128] 23 main questions: impact of
symptoms on daily life, severity of
symptoms, medications
68 questions in total
Comprehensive Time-consuming
Requires lexical skills
Impact of Dry Eye on Everyday Life
(IDEEL) [129,130]
57 items in 3 modules: impact of
dry eye on daily life, treatment
satisfaction, symptoms
Validated by FDA PRO instrument
development guidelines
Very comprehensive
High efﬁcacy for exploring new
therapies
Adequate for clinical trials
Very time consuming to complete
Not adapted for daily clinical
practice
International Sj€ogren's
Classiﬁcation [131,132]
Criteria based on Sj€ogren's
International Collaborative Clinical
Alliance
3 questions
Quick and easy Not developed speciﬁcally for DED
McMonnies [133,134] 14 questions carried out by the
patient
Initial screen test for presence/
absence of dry eye
Mix of several types of questions
Validated
Suitable as a screening
questionnaire
Not adapted for clinical trials
May not distinguish between mild,
moderate or severe DED
Ocular Surface Disease e Quality of
Life (OSD-QoL) [135,136]
26 questions (score 0e100):
including daily activities,
professional activities & handicap,
fear of future/vision loss, emotional
well-being and mood
Adaptable to several types of OSD
Has been shown to provide relevant
information
Not only focused on DED
Questions not validated in English
Ocular Surface Disease Index (OSDI)
[137,138]
12 questions that assess dry eye
symptoms
3 subsections on environmental
triggers, ocular symptoms and
vision-related function
Validated
Simple and fast to answer
Effective discrimination between
mild, moderate or severe DED
Possibility of declaring some
questions as non-adapted to the
situation of the patient
Covers only 1 week of symptoms
Schein [139] Developed to test DED in elderly
cohort
6 questions with 4 grades of
answers
Simple to use 3 questions in the same ﬁeld
No clear deﬁnition of the frequency
of grading
Standard Patient Evaluation of Eye
Dryness (SPEED) [140]
8 questions
Includes questions on severity
Very quick to use
Covers 3 month period prior to
completing
Does not contain questions
regarding task and environmental
triggers
Women's Health Study [141,142] 11 questions Includes QoL questions that
determine effect of DED on daily
living
Requires more validation as is
poorly described in literature
G. Geerling et al. / The Ocular Surface 15 (2017) 179e192184methodologies, there are several emerging technologies that show
promise for improving the diagnostic procedure (Table 1). How-
ever, there is still a challenge to ﬁnd a single reproducible, reliable
and well-accepted test that can be used in general practice. This
need has encouragedmany researchers and companies to develop a
number of increasingly sophisticated instruments as diagnostic
tools that can be adapted for screening for MGD. Some of the most
promising tools are outlined below and have been summarised in
Table 1.
5.1. Interferometry
Interferometry may be used to visually analyse the lipid layer of
the tear ﬁlm [52,53]. One of the ﬁrst interferometers to be devel-
oped was the Tearscope® tear ﬁlm analysis device, which was
launched in 1997 by Keeler Ltd (Windsor, UK) [54,55]. Initially
developed to measure TBUT, the Tearscope® projects a cylindrical
source of white ﬂuorescent light onto the tear ﬁlm lipid layer (TFLL),
which can then be assessed by use of the interference images ob-
tained [56,57]. Comparison of the images allows grades based on
the uniformity and colour of the lipid ﬁlm to be assigned. Its use for
assessing the lipid ﬁlm has been shown to be objective, with good
inter-observer correlation [56,57].
TFLL interference patterns can also be captured using the DR-1camera (Kowa, Nagoya, Japan); severity can be assessed according
to the Yokoi dry eye grading system e grade 1, somewhat grey
colour, uniform distribution; grade 2, somewhat grey colour, non-
uniform distribution; grade 3, a few colours, non-uniform distri-
bution; grade 4, many colours, non-uniform distribution; grade 5,
corneal surface partially exposed [35,58].
More recently, the LipiView® interferometer (TearScience Inc.,
Morrisville, NC, US) has been developed. This device exploits the
principle of broad-spectrum white light interferometry (http://
www.tearscience.com). The patient's eye is illuminated with light
directed at the corneal surface; the light passes through the tear
ﬁlm and is reﬂected into a camera, forming an interference pattern
called an interferogram. The LipiView® interferometer measures
the lipid layer thickness of a deﬁned area of tear ﬁlm and captures
the blink proﬁle during a designated time interval [59]. A positive
correlation between TFLL thickness and expressible meibomian
glands suggests that a low lipid layer thickness indicates a high
probability of MGD. Quantitative results for TFLL behaviour can be
obtained by employing the dynamic lipid layer interference pat-
terns (DLIP) test [60]. The DLIP test measures the interference
pattern of the lipid layer on the central area of the precorneal tear
ﬁlm between blinks, allowing for an evaluation of the elastic
properties of the lipid layer and its ability to produce a stable
interference pattern. Results demonstrated a signiﬁcant difference
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(3.2 ± 1.5 blinks before a change), p < 0.001. Sensitivity and spec-
iﬁcity tests indicated that measurements should be taken after 6.5
consecutive blinks in order to obtain the most consistent and
reliable results [60].
A few years ago, a number of studies demonstrated that inter-
ferometry was a useful tool in diagnosing both the presence and
severity of DED [61]. However, its value as a screening test for MGD
has now been demonstrated by Eom et al. in a study that differ-
entiated between 25 individuals with normal eyes (control group)
and 30 patients with obstructive MGD by measuring and
comparing the thickness of the TFLL. The lipid layer was shown to
be signiﬁcantly thicker in the control group vs the group with
obstructive MGD (p ¼ 0.028) [62]. In a separate study of 110 pa-
tients (199 eyes) from a DED population, there was a signiﬁcant
correlation between the number of expressible meibomian glands
and the lipid layer thickness, suggesting a higher probability of
MGD in patients with a low lipid layer thickness [59].
5.2. Non-contact meibography
Meibography is a specialised technique developed solely for
directly observing the morphology of meibomian glands in vivo
[63]. Traditional meibography (developed in the late 1970s) ob-
serves the structure of meibomian glands in silhouette by illumi-
nating the eyelids from the skin side via a probe applied directly to
the eyelid [64,65]. While providing highly useful images for many
years, the technique suffered from a number of limitations; these
included a lack of documentation and detailed analysis of the
technique and the need to take several images in order to form a
composite panoramic image of meibomian gland morphology [66].
It was also often very uncomfortable for the patient owing to the
heat, brightness and sharpness of the probe [66]. Recently, non-
invasive methods of meibography have been explored that avoid
causing the patient discomfort and permit simpler observation of
the upper and lower eyelids [64,65]. The technique, as seen for
example with the Topcon BG-4M Non-Contact Meibography Sys-
tem (TopconMedical Laser Systems, Inc., Santa Clara, CA, US), uses a
slit-lamp biomicroscope and video camera with an infrared ﬁlter. It
enables detection of meibomian gland dropout, shortening, dilation
and distortion. It is a less time-consuming technique than the
conventional contact methods, easier to use and more patient
friendly [65]. Recent advancements to the technology now include
mobile, hand-held, pen-shaped systems with an infrared LED ﬁxed
to the camera, which enable videos and images to be captured that
are comparable in quality to previous meibography systems [67].
These portable devices, such as the Meibom Pen (Focus Corpora-
tion, Tokyo, Japan), eliminate the need for a slit lamp and have the
potential to become a common feature in clinical practice. Arita
et al. proposed a scoring system (meiboscore) in which each eyelid
is examined for meibomian gland loss and scored from grade 0 (no
loss of meibomian glands) through grade 3 (the area of loss more
than two thirds of the total meibomian gland area [65].
Many studies have previously conﬁrmed the use of meibog-
raphy for the diagnosis and evaluation of MGD [14,43,44,68]. Non-
contact meibography using a standard infrared video security
camera was examined in 17 patients, and the extent of meibomian
gland loss was measured by digital image analysis [69]. A signiﬁ-
cant correlation between meibomian gland loss and lipid layer
pattern, non-invasive TBUT and OSDI was shown, suggesting that
this technique may have diagnostic value. A recent evaluation of
meibomian gland atrophy using non-contact infrared meibography
concluded that examination of just the lower eyelid is probably
sufﬁcient for the evaluation of meibomian gland atrophy and that
meiboscore correlates with expressible meibomian glands andTBUT, suggesting that in patients with detectable meibomian gland
atrophy, meibomian gland function is impaired. Furthermore,
meibography alone seems insufﬁcient as a single test and has to be
interpreted in the context of other clinical parameters (e.g.
expressible glands and TBUT) for the diagnosis of MGD [70].
Objective analysis of the images derived from non-contact mei-
bography is also being developed using advanced software [71]. An
objective method such as this would permit more subtle
morphological changes in the meibomian gland to be evaluated, as
well as the monitoring of treatment response and dropout associ-
ated with non-responders of meibomian gland-targeted treatment.
In addition to evaluating non-invasive TBUT (see next section),
the Oculus Keratograph 5M is able to examine the meibomian
glands, tear meniscus height and lipid layer. The Keratograph 4
(Oculus) was used to image the meibomian glands of 37 partici-
pants to determine morphological changes in both the upper and
the lower eyelids [72]. Differences in the meibomian gland dropout
score were observed between patients with and without MGD.
These differences were observed whether subjective (p ¼ 0.0004)
or digital (p ¼ 0.001) grading scales were used [72].
5.3. Non-invasive TBUT using keratography
Keratography permits visual assessment of the topography of
the corneal surface, allowing for an analysis of tear ﬁlm stability by
comparing the irregularities in recorded images. A number of
studies have been published that have investigated the non-
invasive technique for its clinical usefulness in screening for DED
and MGD [72,73].
Non-invasive TBUT using a keratograph was clinically assessed
in 100 patients using either the Oculus Keratograph (Oculus, Inc.,
Lynnwood, WA, US) or the standard Keeler Tearscope (Keeler Ltd,
Windsor, UK) [73]. The Oculus Keratograph was found to detect
very early tear ﬁlm changes, which may be an advantage, but it
recorded signiﬁcantly lower non-invasive TBUTs than the Tear-
scope [73]. The objective measurement of tear break-up with the
Oculus Keratograph may have clinical use by providing information
on the location of multiple breaks, the area covered and any ﬁlm
reformation [73].
The Oculus Keratograph 5M (http://www.oculus.de) represents
the latest technology in keratographs. It is an advanced, non-
contact corneal topographer with integrated keratometer and
colour camera. Multifunctional ophthalmic instruments such as
this are able to use an inbuilt infrared camera for meibography [71].
There are many other instruments available that employ the
technique of measuring non-invasive TBUT using keratography, and
this list is not intended to be comprehensive, but only to highlight
the technology as one that shows potential for improving the
diagnosis of MGD.
5.4. In vivo confocal laser microscopy
In vivo confocal laser microscopy is a contact technique that is
employed in many clinical areas and has also been trialled in the
examination of meibomian glands. With the ability to take multiple
images, in vivo confocal laser microscopy allows extensive exami-
nation of the subject of interest, including diffuse disease. It can be
used to examine acinar density and diameter, secretion reﬂectivity
and periglandular inﬂammation for their diagnostic values in pa-
tients with MGD [22,74,75]. The technique involves scanning the
inverted eyelid and meibomian glands while moving the appla-
nating lens along the eyelid length. The procedure requires an
experienced examiner, can take up to 10 min, is considered to be
more intrusive than meibography and requires the use of topical
anaesthesia.
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MGDwas examined in a prospective study of 20 patients withMGD
compared with 15 controls, using the parameters of acinar unit
density and diameter [22]. The study demonstrated that patients
with MGD had an increased acinar unit diameter with decreased
mean acinar unit density compared with the control group
(p < 0.05, for both measures) [22]. Both parameters were signiﬁ-
cantly associated with meibomian gland dropout and meibomian
gland expressibility grades (p < 0.05) [22]. The images also indi-
cated that enlargement of the acinar units was due to inspissation
of meibum secretions and glandular atrophy with periglandular
ﬁbrosis [22].
Confocal microscopy also has the potential to diagnose MGD
with high sensitivity and speciﬁcity [76]. A prospective, controlled
study of 20 patients with MGD and 26 controls found that all
confocal microscopy parameters correlated strongly with tear
functions, ocular surface staining, meibomian gland expressibility
and dropout grades.
Finally, this emerging technology has proved to be useful as a
diagnostic adjunct tool for in vivo examination of meibomian
glands [75]. Confocal microscopy may be of great value in imaging
resident Demodex mites in the meibomian gland oriﬁces [31].
Although a causal role of Demodex infestation in MGD pathology
has not been established, confocal microscopy has identiﬁed low
frequencies of Demodex mites in the eyelids and glands of healthy
subjects, whereas levels are increased in the skin, lash follicles or
even meibomian glands of patients with MGD-related DED, ble-
pharitis and rosacea [31,77]. When such observations are consid-
ered together with reports of successful eradication of Demodex
mites in patients with rosacea following targeted antimicrobial
treatment, a pathogenic role for Demodex infestation in ocular
disease cannot be wholly discounted [77].
6. Recommendations for managing MGD
Optimal management of MGD is important as the clinical chal-
lenge of MGD goes beyond the ocular surface. For example, MGD is
implicated in unfavourable outcomes after various surgical pro-
cedures [27]. Active blepharitis may increase the presence of bac-
teria on the ocular surface and pose a risk for the development of
postoperative endophthalmitis [78]. Additionally, MGD can cause
serious corneal disease if progression to permanent gland atrophy
occurs [79].
The principal goal of all treatments of MGD is to increase the
quality and quantity of meibomian expression and thus improve
patient symptoms, with early treatment being of particular
importance [6]. Existing treatment algorithms for MGD recom-
mend therapies according to the severity of the condition, begin-
ning with eyelid hygiene and progressing to the addition of topical
lubricants (lipid-containing sprays, tears or ointments); topical and
systemic antibiotics with anti-inﬂammatory properties, such as
macrolides and tetracyclines; anti-inﬂammatory agents or omega-
3 fatty acid dietary supplementation; and topical steroids [1,80].
Some of the traditional and effective approaches to managing MGD
are outlined below, along with a review of some of the emerging
treatment options and devices that are available.
6.1. Eyelid hygiene
Eyelid hygiene is the cornerstone of MGD treatment and con-
sists of two components: eyelid warming and eyelid massage [80].
The improvement in symptoms of MGD with eyelid hygiene was
recently conﬁrmed in a randomized controlled trial [81]. It is rec-
ommended that patients withMGD apply hot compresses for 5 min
in the morning and evening to loosen the meibum, followed bymassage of the closed eyelid. The importance of eyelid hygiene in
the management of MGD is highlighted by the potential involve-
ment of microbes, e.g. Staphylococcus sp., P. acnes, Bacillus oleronius
and the Demodex mite, in the pathology of MGD-associated DED
(Fig. 1). As previously discussed, these microbes are thought to
contribute to the changes in meibum secretion that result in an
increased melting temperature and further inﬂammation [16].
There are several preparations available for eyelid cleansing, some
of which contain tea tree oil, which has been shown to be effective
in eradicating Demodex mites (although the pathogenic role of
Demodex mites in MGD is uncertain) [82].
Application of warmth to the meibomian glands is believed to
provide beneﬁt by melting the meibomian lipids. Some studies
have suggested that MGD can cause meibomian glands to produce
secretions with reduced levels of lipids, esters and free sterols
compared with those produced by normal meibomian glands [83].
Meibum in patients with MGD has a higher melting temperature
(35 C) compared with that in normal control individuals (32 C)
and is more stagnant and viscous [80]. Thus, a therapy that involves
warming the eyelid to melt the pathologically altered meibomian
lipids could lead to an improvement in their secretion [80]. After
warming, effective massaging of the eyelids can be achieved by
applying traction on the lateral canthus to keep the eyelids in po-
sition followed by mildly compressing the eyelids upwards or
downwards with a cotton bud, starting from the nasal canthus and
moving laterally toward the lateral canthus [80].
While eyelid warming and eyelid massaging have been shown
to be effective in themanagement of MGD, these methods are often
time consuming and labour intensive, and can lead to patient
compliance problems [84]. Thus, in order to standardise and
simplify the treatment, a number of different devices have been
developed. In a study of 25 patients with MGD-related evaporative
DED, the eyelid-warming device MGDRx Eyebag® (The Eyebag
Company, Halifax, UK) signiﬁcantly improved ocular symptomol-
ogy, non-invasive TBUT, lipid layer thickness, osmolarity, and
meibomian gland dropout and function [85]. Similarly, in another
study of 73 patients with MGD, the eyelid-warming device Ble-
phasteam® (Laboratoires Thea, Clermont-Ferrand, France) was used
twice a day for 3 weeks and was found to signiﬁcantly improve the
symptomatology visual analogue scale score from 63.1 (baseline,
Day 0) to 41.9 on Day 21 (p < 0.001) [86]. A non-wet eyelid-
warming pillow, Azuki no Chikara (Kiribai Chemical, Osaka, Japan;
currently available only in Japan), used repeatedly in patients with
MGD resulted in signiﬁcant and lasting improvements in superﬁcial
punctate keratopathy score, TBUT, meibum grade, tarsal conjunc-
tival temperature and meibomian gland area compared with
baseline values [87]. A dual-paddle heating device has been
developed (MiBo Thermoﬂo; MiBo Medical Group, Dallas, Texas,
US) which can warm, massage, and empty clogged Meibomian
glands on both upper and lower lids simultaneously; patient
symptoms were improved in initial non-randomized studies [88].
Of the new technologies that are now emerging to improve
upon traditional eyelid hygiene techniques, the LipiFlow® system
(www.lipiﬂow.com) has shown some promise. It is a device akin to
a scleral shell inserted under the eyelid combined with a second
outer shell resting on the outside of the lid. While the inner shell
provides heat to the tarsal conjunctiva of both the upper and the
lower eyelids for 12 min, the outer shell simultaneously applies a
massaging pressure to express the meibomian glands [4,59]. A
recent study compared the thermal pulsation device LipiFlow®
with an eyelid-warming device (MeiboPatch®) for themanagement
of MGD in 30 patients [89]. Both techniques increased the number
of functional meibomian glands at Month 3, but LipiFlow® provided
more rapid improvement within the ﬁrst month of treatment.
In a recent prospective, randomized, controlled, crossover,
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compared with the automated thermodynamic treatment (Lipi-
Flow®) for the management of MGD in 31 patients [81]. In the ﬁrst
group, the patients received a detailed explanation once on how to
perform manual eyelid hygiene, including warm compresses and
subsequent massage, and were advised to apply this for the sub-
sequent 3 months, while the second group received a single Lipi-
Flow® treatment as an in-ofﬁce procedure. Only the group
receiving the automated treatment demonstrated a signiﬁcant
improvement of symptoms; however, both groups showed an in-
crease in the number of expressible, functional glands. Since it was
only possible to mask the observer, a placebo effect on symptoms
could not be ruled out. The same authors performed an uncon-
trolled follow-up analysis of 26 patients after 6 months, in partic-
ular to correlate the efﬁcacy of the automated treatment with
meibomian gland atrophy using meibography and meiboscore (a
measure of meibomian gland loss) [90]. When compared with
baseline, at the 6-month follow-up patients receiving a single
LipiFlow® treatment showed reduced symptoms, a higher number
of expressible meibomian glands, increased TFLL thickness,
reduced bulbar redness and a reduced number of eyelid margin
parallel conjunctival folds. The reduction of symptoms and increase
of expressible meibomian glands were signiﬁcantly lower in pa-
tients with severe meibomian gland atrophy (meiboscore score of
6), as visualised by meibography; therefore, these patients should
be regarded as potential non-responders.
Finally, a novel technique to address lid margin irregularities
and obstruction of the gland oriﬁce is the surgical removal of
damaged or infected tissue to aid the healing potential of the
remaining healthy tissue (debridement). In a small, open-label
study (n ¼ 28) to test its effectiveness in patients with MGD who
also showed a thickened line of Marx, the procedure was shown to
provide signiﬁcant symptom relief and improvement inmeibomian
gland function (p ¼ 0.0007) [91]. A less invasive method of
microexfoliation of the lid margins is available with the BlephEx
device (Scope Ophthalmics, West Sussex, UK), which utilises a
rapidly rotating microsponge to remove lid debris and microbial
bioﬁlm from the lid margins [92].
Intense pulsed light (IPL) near the eyelid has been proposed to
improve MGD by causing closing of the abnormal blood vessels,
which are thought to secrete inﬂammatory mediators that cause
malfunction of the glands. A 6-year retrospective review of MGD
patients treated with IPL (n ¼ 91) reported a signiﬁcant improve-
ment in TBUT, and >90% of patients had physician-judged im-
provements in meibum and lid margins [93]. These novel
techniques are not yet validated, and require conﬁrmation of
beneﬁt with additional controlled clinical trials.
6.2. Artiﬁcial lubricants
The addition of a lipid component to artiﬁcial lubricants is
proposed to replenish the lipid layer of the tear ﬁlm [80]. These
artiﬁcial lubricants have been shown to stabilise the TFLL, have a
long residence time in the tear ﬁlm, reduce the tear evaporation
rate and improve the signs of MGD [80,94]. The lipids used in these
artiﬁcial lubricants are as follows:
 Cationorm® (Santen) e mineral oil [95].
 Optive Plus® (Allergan) e highly pure castor oil [96].
 Soothe® XP (Artelac® lipids in Germany; Bausch& Lomb)e light
mineral oil, mineral oil [97].
 Systane® Balance (Alcon) e polar phospholipid surfactant
(dimyristoylphosphatidylglycerol) and mineral oil [98].
Although patients with MGD were not speciﬁcally enrolled, arecent study in 1209 patients with DED found that Optive Plus®was
an effective treatment in a subset of the patient group with lipid-
deﬁcient DED [96].
Moreover, lipid-containing eyelid sprays such as Tears Away
(OCuSOFT liposomal spray have been shown to relieve the symp-
toms of DED andwere favoured over an eye gel preparation [94,99].
The phospholipid liposomal spray is applied to the closed eyelids,
and the liposomes migrate, via the lid margins, into the tear ﬁlm
[100]. Notably, a single application of lipid-containing spray
signiﬁcantly increases tear ﬁlm stability up to 90 min post treat-
ment [100].
EvoTears® (also known as NovaTears®; Ursapharm GmbH/
Novaliq GmbH) has recently been launched in Europe. EvoTears®
contains a single ingredient: perﬂuorohexyloctane (F6H8), a novel
substance from the family of semiﬂuorinated alkanes (SFAs). Pre-
servatives are not required in EvoTears® because it is a completely
non-aqueous solution, meaning that microbial growth is not
possible [101]. In a 6-week observational study of 30 patients with
evaporative DED, EvoTears® signiﬁcantly improved corneal stain-
ing, Schirmer scores, TBUT and OSDI scores from baseline [101].
During this study, three patients experienced mild-to-moderate
hypersensitivity to EvoTears® and stopped treatment, after which
they recovered fully [101]. Two further observational studies are
currently recruiting (NovaTears®; www.clinicaltrials.gov).
In patients with a mixed aetiology of MGD and aqueous-
deﬁcient DED, artiﬁcial tears address problems common to both
conditions; through mechanisms such as reduction of hyper-
osmolarity, reduced friction on blinking, spreading of the TFLL and
dilution of inﬂammatory cytokines in the tears, artiﬁcial tears may
reduce proinﬂammatory stimuli [80].
6.3. Antibiotics and anti-inﬂammatory drugs
Antibiotics are commonly used in the treatment of MGD to
reduce the presence of pathogens that are associated with, but not
necessarily causal of, MGD [80].
Topical antibiotics commonly used to treat MGD include baci-
tracin, fusidic acid, metronidazole, ﬂuoroquinolones, macrolides
(including azithromycin) and tetracyclines [80]. Despite the fact
that the role of bacteria in the pathophysiology of MGD remains
uncertain, topical antibiotics (e.g. azithromycin) appear to be
effective and well tolerated when used in the treatment of MGD
[102]. Azithromycin, a broad-spectrum macrolide antibiotic, has
anti-inﬂammatory properties in addition to antibacterial action and
is the most commonly prescribed MGD treatment in the US [1].
However, there are few clinical studies of azithromycin in patients
with MGD. The mechanism for its anti-inﬂammatory activity is not
completely understood, but it is thought to block the activation of
nuclear factor-kappa B, leading to a decrease in some of the in-
ﬂammatory cytokines such as interleukin-6 and -8 [103]. It has also
been reported to inhibit the production of proinﬂammatory me-
diators by acting directly on the corneal epithelial cells [104], and it
increases expression of the anti-inﬂammatory transforming
growth factor b1, as evaluated by eyelid margin and conjunctival
impression cytology, which may contribute to the anti-
inﬂammatory activity of azithromycin in MGD [105]. Azi-
thromycin has also been shown to restore the composition of
meibum to a near-normal state, probably through an antilipase
effect [106].
Systemic tetracycline derivatives such as oral doxycycline (slow-
release 40 mg doxycycline or 40e100 mg/day for 6e12 weeks) are
often preferred in the management of rosacea and MGD, mainly for
anti-inﬂammatory and lipid-regulating properties rather than
antimicrobial effects [80]. Prevention of proinﬂammatory free fatty
acid release through suppression of lipase production by
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eyelid margin, underlies the predominantly anti-inﬂammatory
rather than antimicrobial action of tetracycline at low systemic
doses [80]. It is important to note that tetracycline should not be
administered to children younger than 8 years of age.
6.4. Cyclosporine
Cyclosporine A is a highly speciﬁc immunosuppressant agent
that primarily affects the action of T lymphocytes [107]. Topical
cyclosporine has been successfully used in the management of DED
for many years, and its indication has now been extended to the
treatment of MGD, where it appears to provide considerable beneﬁt
[1,108,109]. Two small studies in 2006 provided contradictory evi-
dence on its efﬁcacy, which may be due in part to the complex way
that cyclosporine treats MGD [108,110]. In a comparison between
topical cyclosporine 0.05% and placebo for the treatment of MGD,
cyclosporine decreased meibomian gland oriﬁce inclusions (plug-
ging) and improved the objective signs of MGD; however, therewas
no improvement in symptoms over placebo [108]. Conversely, in a
12-week comparison of topical cyclosporine 0.05% and tobramycin
0.3%/dexamethasone 0.1% in patients with posterior blepharitis,
cyclosporine provided signiﬁcant improvement in signs, symptoms
and tests that included eyelid health, Schirmer scores, TBUT, mei-
bomian gland secretion quality and symptoms of blurred vision,
burning and itching [110]. More recently, in a 3-month study of 70
patients with symptomatic MGD and unstable tear ﬁlm, cyclo-
sporine A 0.05% was shown to improve mean OSDI, invasive and
non-invasive TBUT, eyelid margin inﬂammation and meibomian
gland expressibility [109].
These results are encouraging; however, there is a clear unmet
need for further studies of topical cyclosporine in the treatment of
MGD and also ocular rosacea [29,80]. Moreover, there is some
debate surrounding the optimal cyclosporine concentration, with
some physicians believing 0.5% cyclosporine to be more efﬁcacious
than 0.05% in MGD. To date, no study has directly compared the
efﬁcacy and safety of 0.5% with 0.05% cyclosporine in MGD.
6.5. Omega-3 dietary supplementation
In a randomized, placebo-controlled, masked trial, omega-3
dietary supplementation was shown to improve overall OSDI
score, TBUT and meibum score in patients with MGD and ble-
pharitis [111]. Data suggest a beneﬁcial role for oral supplementa-
tion with omega-3 essential fatty acids in improving the signs and
symptoms of MGD [1,80,112]. Further research is required to fully
understand the underlying mechanisms, likely involving non-
speciﬁc anti-inﬂammatory properties and/or inﬂuence on the
fatty acid composition and lipid properties of meibum
[111,113e115].
6.6. Topical corticosteroids
Topical corticosteroids may be used for acute episodes of
inﬂammation or to manage inﬂammatory complications of MGD
[80]. Their effectiveness was demonstrated in a study of 32 patients
with DED [116]. After 30 days of treatment, both the symptom
severity scores and the expression of inﬂammatory markers (e.g.
human leukocyte antigen II) in the conjunctival epithelial cells
were reduced [116].
Although there is no published evidence for the long-term use
of corticosteroids for the management of MGD, long-term corti-
costeroid use is not usually advised as it may lead to complications
such as cataract formation, infections and elevation in intraocular
pressure (of up to 60%) [80,117]. However, topicalglucocorticosteroids should not be used on cutaneous rosacea le-
sions associated with MGD because of their tendency to aggravate
rosacea [118].
6.7. Surgical options
Surgical options for MGD generally involve treating the com-
plications of MGD, such as conjunctivochalasis, entropion, ectro-
pion and horizontal eyelid laxity, rather than the primary disease
[80]. Intraductal meibomian gland probing removes meibomian
gland secretions by mechanically opening and dilating the meibo-
mian gland oriﬁce and duct [119]. This technique is still contro-
versial but was shown to be effective in relieving the symptoms of
obstructive MGD, with 95% of patients experiencing postprocedure
relief and 100% of patients experiencing relief 4 weeks following
the procedure. Participants are currently being recruited for a
randomized, double-blind trial (NCT02256969) investigating the
efﬁcacy of intraductal meibomian gland probing compared with a
sham procedure in patients with refractory MGD [120].
7. Recommendations for managing rosacea-associated MGD
Treatment of rosacea-associated MGD should not be limited to
eyelid hygiene, topical medications or dietary supplements. Oral
doxycycline is highly effective for the management of ocular rosa-
cea [121]. Using the anti-inﬂammatory potential of doxycycline,
recent recommendations favour a long-term treatment of ocular
rosacea of at least 6 months and tapering dosage down slowly
depending on clinical improvement [122]. Its effectiveness was
shown in a study of 39 patients with ocular rosacea associated with
signs of ocular disease, such as telangiectasia and MGD. Doxycy-
cline both improved ocular disease and increased TBUT [123].
Doxycycline monohydrate 40 mg is indicated for the reduction of
papulopustular lesions in adult patients with facial rosacea [124].
Additionally, given the putative role of SIBO in the pathophysi-
ology of rosacea [20,125], optimal management of rosacea-
associated MGD should include oral antibiotics as well as topical
anti-inﬂammatory agents. In a study to test the effectiveness of oral
rifaximin therapy for rosacea patients with SIBO (10 days' treat-
ment), it was demonstrated that the reduction of SIBO led to an
almost complete regression of cutaneous lesions in patients with
rosacea, which was maintained for at least 9 months [20]. In a
separate study of patients with rosacea and SIBO, 14 days of
treatment with oral rifaximin led to a marked improvement in
rosacea symptoms in 46% of patients, andmarked improvements in
all four patients included with medicine-refractory ocular rosacea
and SIBO [19]. Further studies are required to explore the effect of
oral rifaximin therapy, as well as novel therapies such as the Ble-
phEx device and IPL (see Section 6.1), on the ocular symptoms of
rosacea-associated MGD.
8. Conclusion
MGD and MGD-associated diseases are widespread, chronic
conditions that can often be overlooked in the clinic. Symptoms,
which include ocular burning, irritation, itching, dryness and
foreign body sensation, are generally exacerbated by factors that
are part of everyday life, such as computer use, air conditioning and
indoor heating. Equally, these symptoms are common complaints
for a number of ocular surface diseases that include anterior ble-
pharitis, ocular allergies, aqueous-deﬁcient DED and evaporative
(or lipid-deﬁcient) DED. Many of these diseases overlap and pa-
tients may have a hybrid type of DED that is both aqueous deﬁcient
and involves dysfunction of the meibomian glands. Consequently,
diagnosis of the correct ocular surface disease can be challenging,
IPL Intense pulsed light
OCEAN Osmoprotection in Dry Eye Disease e Expert Opinion (a medical education
programme)
OSD Ocular surface disease
OSDI Ocular Surface Disease Index
SIBO Small intestine bacterial overgrowth
TBUT Tear ﬁlm break-up time
TFLL Tear ﬁlm lipid layer
G. Geerling et al. / The Ocular Surface 15 (2017) 179e192 189with patients often having to visit a physician many times in order
to ascertain the underlying cause of the complaint. Patients often
discover that their quality of life is signiﬁcantly reduced by the
disabling symptoms; therefore, they can be frustrated by the
perceived lack of a clear diagnosis and lack of improvement during
treatment. Consequently, it is important to provide accurate and
reliable evaluation tests in order to diagnose their condition as
early as possible to ensure that they are offered the most appro-
priate treatment and management program.
This review highlights the complexities of current resources for
the diagnosis of MGD and presents a visual perspective of how
MGD and DED interact. It simpliﬁes the existing information on
how to differentiate between diagnosis of MGD and rosacea-
associated MGD and summarises some of the emerging technolo-
gies for MGD diagnosis. Expert recommendations are given for the
management of MGD and rosacea-associated MGD as well as
highlighting the differences between them. By treating patients
appropriately and early in the course of their disease, their out-
comes are likely to be greatly improved.
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